Highline Wealth Partners’s SpringWorks Therapeutics SWTX Stock Holding History

Highline Wealth Partners’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-62	Closed	-$2.91K	–	1132
2025 Q2	$2.91K	Hold	62	–	–	﹤0.01%	568
2025 Q1	$2.74K	Buy	+62	New	+$2.85K	﹤0.01%	573

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Highline Wealth Partners's SWTX Position: Q3 2025 in Review

Highline Wealth Partners sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 62 shares — an estimated $2.91K sold.

Highline Wealth Partners first reported a position in SWTX in Q1 2025 and held it in 2 quarters. The position peaked at $2.91K in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Highline Wealth Partners reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Highline Wealth Partners sold 62 SpringWorks Therapeutics shares in Q3 2025, an estimated $2.91K.
Highline Wealth Partners first reported a position in SpringWorks Therapeutics in Q1 2025 and held it in 2 quarters.
Highline Wealth Partners's SpringWorks Therapeutics position peaked at $2.91K in Q2 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Highline Wealth Partners's 13F filing for Q3 2025, filed 14 Oct 2025.